Research > Neurosciences

Neuroimmunology

Number of publications
112
Publications search
  • Sancho--Saldaña, A; Gil-Sánchez, A; González-Mingot, C; Peralta, S; Solana, MJ; Torres, P; Juanes, A; Quibus, L; Ruiz, E; Sanpedro, E; Quirant-Sánchez, B; Martínez-Cáceres, E; Tello, CR; Presas-Rodríguez, S; Rubio, SG; Baron, BP; Ramio-Torrenta, L; Sotoca, J; González-Suarez, I; Eichau, S; Prieto-Gonzalez, JM; Quilez, MRB; Sabin-Muñoz, J; Sánchez-López, AJ; Calatayud, GL; Calles, C; Sempere, AP; Garces, M; Carmona, O; Moral, E; Hervas, JV; Blanco, Y; Sola-Valls, N; Lara, NT; Forero, L; Brieva, L

    Seroprevalence of SARS-CoV-2 in Patients with Multiple Sclerosis under Disease-Modifying Therapies: A Multi-Centre Study

    Journal of Clinical Medicine 12 -. .

    [doi:10.3390/jcm12237243]

  • Brochet, B; Solari, A; Lechner-Scott, J; Piehl, F; Langdon, D; Hupperts, R; Selmaj, K; Patti, F; Brieva, L; Maida, EM; Alexandri, N; Smyk, A; Nolting, A; Keller, B; Montalban, X; Havrdova, EK

    Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study

    MULTIPLE SCLEROSIS JOURNAL 29 1808-1818. .

    [doi:10.1177/13524585231205962]

  • Mingot, CG; Lasaosa, SS; Campas, LC; Canaval, LC; Sánchez, AG; Ruiz, LB; Alonso, MCM; Moncusi, SP; Marsal, JV; Carner, SC; García, FP

    Prophylactic treatment can modify vascular risk biomarkers in high-frequency episodic and chronic migraine patients: a pilot study

    SCIENTIFIC REPORTS 13 19416-19416. .

    [doi:10.1038/s41598-023-44522-8]

  • Koch, MW; Moral, E; Brieva, L; Mostert, J; Strijbis, EM; Comtois, J; Repovic, P; Bowen, JD; Wolinsky, JS; Lublin, FD; Cutter, G

    Relapse recovery in relapsing-remitting multiple sclerosis: An analysis of the CombiRx dataset

    MULTIPLE SCLEROSIS JOURNAL 29 1776-1785. .

    [doi:10.1177/13524585231202320]

  • Vicente-Pascual M; Quilez A; Gil MP; González-Mingot C; Vázquez-Justes D; Mauri-Capdevila G; Sanahuja J; García-Vázquez C; Purroy F

    The influence of organisational management on door-to-needle times for fibrinolytic treatment.

    Neurologia (barcelona, Spain) 38 313-318. .

    [doi:10.1016/j.nrleng.2020.10.010]

  • Vicente-Pascual, M; Quilez, A; Gil, MP; Gonzalez-Mingot, C; Vazquez-Justes, D; Mauri-Capdevila, G; Sanahuja, J; Garcia-Vazquez, C; Purroy, F

    The influence of organisational management on door-to-needle times for fibrinolytic treatment

    NEUROLOGIA 38 313-318. .

    [doi:10.1016/j.nrl.2020.10.014]

  • González-Mingot, C; Miana-Mena, FJ; Iñarrea, PJ; Iñiguez, C; Capablo, JL; Osta, R; Gil-Sánchez, A; Brieva, L; Larrodé, P

    Mitochondrial Aconitase Enzymatic Activity: A Potential Long-Term Survival Biomarker in the Blood of ALS Patients

    Journal of Clinical Medicine 12 -. .

    [doi:10.3390/jcm12103560]

  • Torres P; Sancho-Saldaña A; Gil Sánchez A; Peralta S; Solana MJ; Bakkioui S; González-Mingot C; Quibus L; Ruiz-Fernández E; San Pedro-Murillo E; Brieva L

    A prospective study of cellular immune response to booster COVID-19 vaccination in multiple sclerosis patients treated with a broad spectrum of disease-modifying therapies.

    JOURNAL OF NEUROLOGY 270 1-12. .

    [doi:10.1007/s00415-023-11575-8]

  • Gil-Sanchez A; Canudes M; Valcheva P; Nogueras L; González-Mingot C; Hervás JV; Peralta S; Solana MJ; Brieva L

    Effects of vortioxetine on cognition and fatigue in patients with multiple sclerosis and depression: a case series study.

    CNS & Neurological Disorders-Drug Targets 23 395-401. .

    [doi:10.2174/1871527322666230321093133]

  • Lleixà C; Caballero-Ávila M; Pascual-Goñi E; Martín-Aguilar L; Vidal N; Tejada C; Valdés-Hevia E; Zárate E; Vesperinas A; Collet R; Franco-Leyva T; Martínez-Martínez L; Moga E; Cortés-Vicente E; Rojas-García R; Gómez-Anson B; Gil A; González-Mingot C; Brieva L; Martínez-Yélamos S; Querol L

    Antibodies against the flotillin-1/2 complex in patients with multiple sclerosis.

    Brain Communications 5 -. .

    [doi:10.1093/braincomms/fcad109]

  • de la Maza, SS; Gómez-Ballesteros, R; Borges, M; Martín-Martínez, J; Sotoca, J; Alonso, A; Caminero, AB; Borrega, L; Sánchez-Menoyo, JL; Barrero-Hernández, FJ; Calles, C; Brieva, L; Blasco-Quílez, MR; García-Soto, JD; del Campo-Amigo, M; Navarro-Cantó, L; Agüera, E; Garcés-Redondo, M; Carmona, O; Gabaldón-Torres, L; Forero, L; Hervàs, M; Medrano, N; Maurino, J; Castillo-Triviño, T

    Detecting disability using self-reported and clinical assessments in early-stage relapsing-remitting multiple sclerosis: Looking for a complementary approach

    Multiple Sclerosis Journal-Experimental Translational And Clinical 9 -. .

    [doi:10.1177/20552173231169475]

  • Monreal, E; Fernandez-Velasco, JI; Garcia-Sanchez, MI; Sainz de la Maza S; Llufriu, S; Alvarez-Lafuente, R; Casanova, B; Comabella, M; Ramio-Torrenta, L; Martinez-Rodriguez, JE; Brieva, L; Saiz, A; Eichau, S; Cabrera-Maqueda, JM; Villarrubia, N; Espiño M; Perez-Miralles, F; Montalban, X; Tintore, M; Quiroga-Varela, A; Dominguez-Mozo, MI; Rodriguez-Jorge, F; Chico-Garcia, JL; Lourido, D; Alvarez-Cermeno, JC; Masjuan, J; Costa-Frossard, L; Villar, LM

    Association of Serum Neurofilament Light Chain Levels at Disease Onset With Disability Worsening in Patients With a First Demyelinating Multiple Sclerosis Event Not Treated With High-Efficacy Drugs.

    JAMA Neurology 80 397-403. .

    [doi:10.1001/jamaneurol.2023.0010]